{"blog": [], "keywords": [{"value": "Pershing Square Capital Management", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Ackman, William A", "name": "persons", "rank": "3", "is_major": "Y"}, {"value": "Hedge Funds", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/ackman-defends-pershing-squares-large-stake-in-valeant.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Landon", "role": "reported", "organization": "", "rank": 1, "qualifier": "Jr"}], "original": "By LANDON THOMAS Jr"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/07/business/07db-ackman/07db-ackman-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/07db-ackman/07db-ackman-articleLarge.jpg", "xlargeheight": "392", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 392}, {"url": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "510", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "William A. Ackman said the drug company Valeant was undervalued and had potential but its decline had affected his firm, Pershing Square.", "pub_date": "2016-04-07T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Business Briefing; Ackman Defends Holding in Beleaguered Valeant", "main": "Ackman Defends Pershing Square\u2019s Large Stake in Valeant"}, "print_page": "2", "snippet": "William A. Ackman said the drug company Valeant was undervalued and had potential but its decline had affected his firm, Pershing Square.", "_id": "57054e9638f0d86865ca518f", "slideshow_credits": null, "abstract": "Pershing Square Capital Management owner William A Ackman admits he underestimated complexities surrounding Valeant Pharmaceuticals; Ackman's hedge fund was negatively impacted when troubled drug firm's stock fell sharply last quarter. "}